Key result
High-sensitivity troponin assays improve detection of myocardial injury and risk-stratification, though challenges remain in distinguishing acute from chronic elevations and type 1 from type 2 MI.
High-sensitivity troponin assays improve detection of myocardial injury and risk stratification, though challenges remain regarding interpretation of elevations and reference values.
Answers are grounded in this paper and cite their sources.
Refines hs-troponin use for injury detection in practice; leaves open standardized thresholds for acute vs chronic and type 1 vs 2 MI.
High-sensitivity troponin (hsTn) assays are used clinically in most parts of the world and are expected to be approved by the US FDA for clinical use in the USA soon. Clinical use of hsTn leads to improvements in the detection of myocardial injury, shorter time to ruling out acute myocardial infarction, improved risk-stratification of patients with heart failure and atrial fibrillation among others. HsTn may also guide strategies for primary and secondary prevention of cardiovascular disease. However, unmet challenges remain, including distinguishing between acute and chronic hsTn elevations, distinguishing between type 1 and type 2 acute myocardial infarction and determining whether to use gender-neutral or gender-specific reference values.
No takes yet. Share an insight, caveat, or question.
Korley et al. (2014) conducted a review in Cardiovascular disease. High-sensitivity troponin (hsTn) assays was evaluated. High-sensitivity troponin assays improve detection of myocardial injury and risk-stratification, though challenges remain in distinguishing acute from chronic elevations and type 1 from type 2 MI.
Synapse has enriched 10 related papers. Consider them for comparative context: